Issue 21, 2023

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography

Abstract

Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [18F]BiPET-2, and its in vitro and preclinical evaluation in glioblastoma models.

Graphical abstract: Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography

Supplementary files

Article information

Article type
Communication
Submitted
31 Aug 2022
Accepted
14 Feb 2023
First published
14 Feb 2023

Chem. Commun., 2023,59, 3126-3129

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography

C. G. F. Dickmann, A. F. McDonald, N. Huynh, A. Rigopoulos, Z. Liu, N. Guo, L. D. Osellame, M. A. Gorman, M. W. Parker, H. K. Gan, A. M. Scott, U. Ackermann, I. J. G. Burvenich and J. M. White, Chem. Commun., 2023, 59, 3126 DOI: 10.1039/D2CC04813B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements